WO2009015557A1 - Composition pharmaceutique destinée au traitement du diabète et son procédé de préparation - Google Patents

Composition pharmaceutique destinée au traitement du diabète et son procédé de préparation Download PDF

Info

Publication number
WO2009015557A1
WO2009015557A1 PCT/CN2008/001383 CN2008001383W WO2009015557A1 WO 2009015557 A1 WO2009015557 A1 WO 2009015557A1 CN 2008001383 W CN2008001383 W CN 2008001383W WO 2009015557 A1 WO2009015557 A1 WO 2009015557A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
extract
ethanol
pharmaceutical composition
water
Prior art date
Application number
PCT/CN2008/001383
Other languages
English (en)
French (fr)
Inventor
Xiaolin Tong
Yonghong Zhu
Shuiping Zhou
Xiuhui E
Shuangming Wang
Zhongting Xia
Original Assignee
Tianjin Tasly Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN2007100585744A external-priority patent/CN101357183B/zh
Priority claimed from CN2007100585725A external-priority patent/CN101357181B/zh
Priority claimed from CNA2007100585710A external-priority patent/CN101357180A/zh
Priority claimed from CN200710058573XA external-priority patent/CN101357182B/zh
Priority to BRPI0812792A priority Critical patent/BRPI0812792B8/pt
Priority to EP08783574A priority patent/EP2172207B1/en
Priority to AU2008281227A priority patent/AU2008281227B2/en
Priority to NZ581525A priority patent/NZ581525A/en
Application filed by Tianjin Tasly Pharmaceutical Co. Ltd. filed Critical Tianjin Tasly Pharmaceutical Co. Ltd.
Priority to CA2687492A priority patent/CA2687492C/en
Priority to KR1020107003490A priority patent/KR101462984B1/ko
Priority to JP2010518477A priority patent/JP5508264B2/ja
Priority to DK08783574.0T priority patent/DK2172207T3/da
Priority to US12/601,236 priority patent/US8637092B2/en
Priority to RU2009144878/15A priority patent/RU2485968C2/ru
Publication of WO2009015557A1 publication Critical patent/WO2009015557A1/zh
Priority to HK10104520.9A priority patent/HK1138206A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233Bupleurum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • A61K36/428Trichosanthes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708Rheum (rhubarb)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888Pinellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a process for the preparation of a pharmaceutical composition for treating diabetes, and a pharmaceutical composition prepared by the method. Background technique
  • Diabetes is a chronic progressive life-threatening disorder caused by disorders of sugar, protein and fat metabolism in the body, characterized by hyperglycemia and diabetes. This disease can lead to heart and kidney complications, blindness and amputation. In recent years, clinical observations have shown that the incidence of diabetes is increasing year by year. At present, there are about 150 million diabetes patients in the world, and the number of diabetes in China is over 40 million. Among the cases of diabetes, a small number are insulin-dependent diabetes mellitus (type I), and most are non-insulin-dependent diabetes mellitus (sputum type). Most people with diabetes need to take medication for life.
  • type I insulin-dependent diabetes mellitus
  • Sputum type non-insulin-dependent diabetes mellitus
  • diabetes treatment is still dominated by chemical synthetic drugs, such as sulfonamides, biguanides, glucosidase inhibitors, glinides and insulin sensitizers.
  • chemical synthetic drugs such as sulfonamides, biguanides, glucosidase inhibitors, glinides and insulin sensitizers.
  • traditional Chinese medicine has a long history of preventing and treating diabetes. After thousands of years of practice, it has accumulated a lot of valuable experience and formed a unique academic system.
  • Chinese medicine classics record many traditional Chinese medicines with hypoglycemic effects, such as Zexie, Zhimu, American ginseng, Pueraria, Rehmannia, and pollen.
  • Traditional Chinese medicine treatment of diabetes is based on clinical symptoms and treatment. However, there is no good treatment in the period of impaired glucose tolerance and early onset of diabetes.
  • Diabetes is the first to be responsible for the liver and stomach.
  • the stagnation of heat is the pathological basis of diabetes, "Mu Yu Da Zhi”, “Tu Yu Yu Zhi”, so when it is based on dredging, SP "will be the owner of the disease, and First, because of it.”
  • Sugar-sensitive spirits open the stomach and clear the stomach, nourishing yin and reducing fire, phlegm and phlegm, and treating both the symptoms and the symptoms.
  • the stagnation is clear, the qi is self-recovering.
  • An object of the present invention is to provide a pharmaceutical composition for treating diabetes which has the following composition, which is produced by the following method of the present invention, thereby solving the above-mentioned problems existing in the prior art. problem.
  • a further object of the present invention is to provide a process for the preparation of a pharmaceutical composition of the present invention, which comprises the following extracts prepared from raw materials: 5-40 parts of trichosanthin, 10-30 parts of Bupleurum, and medlar 3-15 parts, 1-6 parts of rhubarb, 1-12 parts of Pinellia, 3-15 parts of astragalus, 1-12 parts of berberine, 3-15 parts of white peony and 5-20 parts of ebony, and optionally containing pharmacy An acceptable excipient; the composition is prepared by one of the following methods:
  • Method one includes the following steps:
  • adding an excipient to the above-mentioned extract to prepare a pharmaceutically acceptable dosage form includes the following steps:
  • the preferred weight ratios of various raw materials are: 9 parts of trichosanthin, 12 parts of Bupleurum, 9 parts of medlar, 3 parts of rhubarb, 6 parts of Pinellia, 9 parts of astragalus, and berberine 6 Servings, 9 white peony and 9 ebony.
  • the pharmaceutical composition of the present invention can also be added to the hawthorn in the formula, because the behenic acid is succulent and yin, which can prevent the spleen from being too suffocating and the bitter acid. sweet. It has a good effect in combination with Kaiyuqing.
  • the ratio of parts by weight of various raw materials is: 5-40 parts of trichosanthin, 10-30 parts of Bupleurum, 3-15 parts of medlar, 1-6 parts of rhubarb, 1-12 parts of Pinellia ternata 3-15 parts of astragalus, 1-12 parts of berberine, 3-15 parts of white peony, 5-20 parts of ebony and 3-15 parts of hawthorn.
  • the weight ratio of various raw materials in the pharmaceutical composition of the present invention is: 10-30 parts of trichosanthin, 10-30 parts of Bupleurum, 3-15 parts of medlar, 1-6 parts of rhubarb, and Pinellia 1 -12 parts, 3-15 parts of astragalus, 1-12 parts of berberine, 3-15 parts of white peony, 5-20 parts of ebony and 3-15 parts of hawthorn.
  • the weight ratio of various raw materials in the pharmaceutical composition of the present invention is: 30 parts of trichosanthin, 12 parts of Bupleurum, 9 parts of medlar, 3 parts of rhubarb, 6 parts of Pinellia, 9 parts of astragalus, and berberine 6 Parts, 9 times of white peony, ebony 15 parts and 9 parts of hawthorn; or 15 parts of trichosanthin, 12 parts of Bupleurum, 9 parts of medlar, 3 parts of rhubarb, 6 parts of Pinellia, 9 parts of Astragalus, 6 parts of Coptis, 9 parts of white peony, 15 parts of ebony and hawthorn 9 copies.
  • the following operating conditions are preferably employed:
  • step (2) it is preferred to extract twice by reflux, using water 10 times the weight of the medicinal material for 1.5 hours each time.
  • the extract is concentrated to a ratio of the original medicinal weight (kg) to the volume (L) of the concentrate of 1:1.
  • the concentration of ethanol added is preferably from 90 to 100%, preferably 95%.
  • the resulting concentrate preferably has an alcohol content of 70%. Since the above-mentioned water extraction and alcohol precipitation method of the present invention is employed, the content of the active ingredient in the traditional Chinese medicine composition prepared by the method is remarkably improved, and the content of impurities is remarkably reduced, thereby reducing the dose to be administered.
  • step (2) it is preferred to add water twice to reflux, and use 10 times of water per weight of the medicinal material for one hour each time.
  • the macroporous resin is preferably of the AB-8 type.
  • the weight ratio of the resin to the medicinal material is preferably from 1:1.5 to 1:3, more preferably 1:2.
  • the loading rate of the extract is preferably 4-6 column volumes per hour.
  • the amount of water washing is preferably 4-6 column volumes.
  • the concentration of ethanol used for elution is preferably from 80% to 95%, further preferably 90%.
  • the amount of ethanol used is preferably 2 to 5 column volumes.
  • the temperature at which ethanol is recovered under reduced pressure is preferably 60-80 ° C, and ethanol is recovered under reduced pressure to obtain an extract having a relative density of 1.25-1.35, preferably a relative density of 1.30.
  • the above preparation method of the invention adopts a water extraction process to ensure that the water-soluble active ingredients, such as saikosaponin, berberine (berberine hydrochloride), baicalin, chrysophanol, paeoniflorin, synephrine, etc., are maximized.
  • the content of the active ingredient in the traditional Chinese medicine composition of the present invention is remarkably improved, the content of impurities is greatly reduced, thereby reducing the dose of administration, and also ensuring the stability between product batches.
  • the following operating conditions are preferably employed:
  • the concentration of the ethanol used is 75-90%, preferably 80%; preferably, the extract is refluxed twice, each time using 10 times the weight of the medicinal material of the step (2), each extraction 1.5 hours.
  • step (3) it is preferred to add the other medicinal materials to the dregs obtained in the previous step, and extract them twice with water, each time the amount of water is the other medicinal materials added in the step (3) and the step (2).
  • the extract is concentrated to a ratio of the original medicinal weight (kg) to the volume (L) of the concentrate of 1:1.
  • concentration of ethanol added is preferably from 90 to 100%, more preferably 95%, and the alcohol content of the concentrate is from 65 to 75%, preferably 70%.
  • the raw materials such as Bupleurum, Radix Paeoniae Alba, Radix Paeoniae Alba, Rhubarb, Radix Astragali, Rhizoma Coptidis, etc. are firstly extracted, and the residue is combined with other herbs to extract water, thereby ensuring that the active ingredients of the six herbs are fully extracted;
  • Other medicinal materials extract only the active ingredient therein by water because the active ingredients therein are all water-soluble.
  • step (2) it is preferred to extract twice with water under reflux, using 10 times the weight of scutellaria each time for 1 hour.
  • the holding temperature is preferably 75 to 85 ⁇ , and more preferably 80 °C.
  • step (3) it is preferably extracted twice with ethanol under reflux, each time using 10 times the weight of berberine in ethanol for 2 hours each time.
  • the concentration of ethanol used is preferably 70-85%, more preferably 75%.
  • the pH adjuster is preferably concentrated hydrochloric acid.
  • the step (4) it is preferred to extract the remaining medicinal materials twice with water, and add 10 times the water of the medicinal material in the step (4) for 1 hour each time.
  • the combined extracts are concentrated to a relative density of 1.03-1.07, preferably a relative density of 1.05.
  • the ethanol extract is concentrated to an extract having a relative density of 1.25 to 1.35, preferably having a relative density of 1.30.
  • the astragalus, berberine and other medicinal materials are separately extracted, and respectively subjected to water extraction or alcohol extraction under a certain pH condition according to their own properties, so as to make the active ingredient in the traditional Chinese medicine composition of the present invention.
  • the content is significantly increased, and the amount of impurities is greatly reduced, thereby reducing the dose administered.
  • the pharmaceutical composition for treating diabetes having the above composition can be prepared by the above method of the present invention, and the pharmaceutical composition of the present invention can be prepared into any conventional preparation by a conventional method of a traditional Chinese medicine preparation using conventional excipients in the art. .
  • the above-mentioned raw material medicine is ground into a powder, or the prepared extract is dried, pulverized, sieved, ground into a powder, or it is made into a tablet or a capsule orally, or it is made into an injection or the like.
  • the pharmaceutical composition prepared by the method of the present invention has a blood sugar lowering effect and has a good therapeutic effect on diabetes.
  • ethanol concentration or the alcohol content that is, the amount of ethanol contained in the system
  • a percentage it means a volume percentage concentration or a volume percentage unless otherwise specified.
  • Example 1 The drug of the present invention and its beneficial effects are further illustrated by the following examples and test examples, but the scope of the present invention is not limited in any way.
  • Example 1 The drug of the present invention and its beneficial effects are further illustrated by the following examples and test examples, but the scope of the present invention is not limited in any way.
  • Drug formula 750g of trichosanthin, 1500g of Bupleurum, 450g of medlar, 150g of rhubarb, 150g of Pinellia, 450g of Radix Scutellariae, 150g of Rhizoma Coptidis, 450g of Radix Paeoniae Alba and 750g of ebony.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 9-flavored medicinal material is extracted twice with 10 times its weight of water, and the extract is filtered for 1.5 hours each time.
  • the extract is concentrated under reduced pressure to the original medicinal material weight (kg) and the volume of the concentrated liquid (L).
  • the ratio is 1: 1, adding 90% ethanol to 65% alcohol content, filtering, and concentrating into a thick paste under reduced pressure.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, white peony root, medlar, rhubarb, astragalus, and berberine were extracted twice with 10 times the weight of 75% ethanol, and the extract was filtered for use for 1.5 hours each time;
  • the extract is concentrated under reduced pressure to the original
  • the ratio of the weight of the medicinal material (kg) to the volume (L) of the concentrated solution is 1: 1, 90% ethanol is added to the alcohol content of 65%, filtered, and used;
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Example 4 Using the same formulation as in Example 1, the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 7 herbs were added with 10 times their weight of water and refluxed twice for 1 hour each time; the extract was concentrated under reduced pressure to a relative density of 1.03, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; After standing, filtered, the ethanol was recovered to a relative density of 1.25, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula Trichosanthin 1200g, Bupleurum 900g, medlar 450g, rhubarb 180g, Pinellia 360g, Radix Scutellariae 450g, Coptis 360g, Angelica sinensis 450g and ebony 600g.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica, Rhizoma, Rhubarb, Astragalus, and Rhizoma Coptidis are extracted twice with 10 times their weight and 90% ethanol, 1.5 hours each time, and the extract is filtered and used;
  • the ratio of the initial medicinal material weight (kg) to the volume (L) of the concentrate is 1: 1, adding absolute ethanol to the alcohol content of 75%, filtered, and set aside;
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the above 9 herbs were added to the water for 2 times, and each time 49.5 kg of water was added, one hour each time. Let the extract cool down, Filter, merge.
  • the AB-8 type macroporous adsorption resin has a macroporous adsorption resin dosage of 1.7 kg and a loading speed of 6 column volumes per hour. First elute with 6 column volumes of water and discard the aqueous eluent. Then, it was eluted with 5 column volumes of 95% ethanol, and the alcohol eluates were combined. The ethanol was recovered under reduced pressure at 70 Torr to a relative density of 1.35, dried under vacuum at 90 Torr, and pulverized through a 80 mesh sieve.
  • Starch is compressed into tablets in the obtained dry paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 7 herbs were added with 10 times their weight of water for 2 times, 1 hour each time; the extract was concentrated under reduced pressure to a relative density of 1.07, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; The solution was filtered, and ethanol was recovered to a relative density of 1.35, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula 630g of gerbera, 840g of Bupleurum, 630g of medlar, 210g of rhubarb, 420g of Pinellia, 630g of astragalus, 420g of berberine, 630g of white peony and 630g of ebony.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica sinensis, Radix Paeoniae Alba, Rhubarb, Astragalus, and Rhizoma Coptidis are extracted twice with 10 times their weight of 80% ethanol, 1.5 hours each time, and the extract is filtered and used;
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the above 9 herbs were added to the water for 2 times, and 50.4 kg of water was added each time for 1 hour. Let the extract cool down, filter, and combine.
  • the AB-8 type macroporous adsorption resin has a macroporous adsorption resin dosage of 2.52 kg and a loading rate of 5 column volumes per hour. First elute with 5 column volumes of water. The water eluate was discarded. Then, it was eluted with 3 column volumes of 90% ethanol, and the alcohol eluates were combined. The ethanol was recovered under reduced pressure at 70 ° C to a relative density of 1.30, dried under vacuum at 80 Torr, and the dry paste was pulverized through an 80 mesh sieve.
  • a concentrated pellet was prepared by adding microcrystalline cellulose to the obtained dry paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 7 herbs were added with 10 times their weight of water for 2 times, one hour each time; the extract was concentrated under reduced pressure to a relative density of 1.05, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; The solution was filtered, and the ethanol was recovered to a relative density of 1.30, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula 750g of trichosanthin, 1500g of Bupleurum, 450g of medlar, 150g of rhubarb, 150g of Pinellia, 450g of Radix Scutellariae, 150g of Rhizoma Coptidis, 450g of Radix Paeoniae, 750g of ebony and 450g of Hawthorn.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 10 herbs were extracted twice with 10 times the weight of water, and the extract was filtered for 1.5 hours each time.
  • the extract was concentrated under reduced pressure until the ratio of the original drug weight (kg) to the volume (L) of the concentrate was 1 : 1, add 90% B
  • the alcohol was added to an alcohol content of 65%, filtered, and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica sinensis, Radix Paeoniae Alba, Rhubarb, Astragalus, and Rhizoma Coptidis are extracted twice with 10 times the weight of 75% ethanol, 1.5 hours each time, the extract is filtered, and used;
  • the extract is concentrated under reduced pressure.
  • the ratio of the original medicinal material weight (kg) to the volume (L) of the concentrate is 1:1, 90% ethanol is added to the alcohol content of 65%, filtered, and set aside;
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method - the above 10 herbs were refluxed twice with water, and 52.5 kg of water was added each time for 1 hour. The extract will be allowed to cool, filtered, and combined.
  • the AB-8 type macroporous adsorption resin has a macroporous adsorption resin dosage of 3.5 kg and a loading rate of 4 column volumes per hour. First elute with 4 column volumes of water. The water eluate was discarded. Then, it was eluted with 2 column volumes of 80% ethanol, and the alcohol eluates were combined. The ethanol was recovered under reduced pressure at 80 Torr to a relative density of 1.35, dried under vacuum at 70 Torr, and the dried paste was pulverized through an 80 mesh sieve.
  • Lactose was added to the obtained dry paste to prepare a capsule.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 8 herbs were added with 10 times their weight of water for 2 times, 1 hour each time; the extract was concentrated under reduced pressure to a relative density of 1.07, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; The solution was filtered, and the ethanol was recovered to a relative density of 1.25, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula Trichosanthin 1200g, Bupleurum 900g, medlar 450g, Rhubarb 180g, Pinellia 360g, Radix Scutellaria 450g, Coptis 360g, White peony 450g, Wumei 600g and Hawthorn 450g.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 10 herbs were extracted twice with 10 times the weight of water, and the extract was filtered for 1.5 hours each time.
  • the extract was concentrated under reduced pressure until the ratio of the original drug weight (kg) to the volume (L) of the concentrate was 1 : 1, add anhydrous ethanol to 75% alcohol content, filter, and concentrate to a thick paste under reduced pressure.
  • the pharmaceutical composition of the present invention was prepared by the following method - Bupleurum, Angelica, Rhizoma, Rhubarb, Astragalus, and Coptis were refluxed twice with 10 times the weight of 90% ethanol, each time. 1.5 hours, the extract was filtered and used;
  • the ratio of the initial medicinal material weight (kg) to the volume (L) of the concentrate is 1: 1, adding absolute ethanol to the alcohol content of 75%, filtered, and set aside;
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the above 10 herbs were added to the water for 2 times, and each time, 54 kg of water was added, one hour each time. Let the extract cool down, filter, and combine. Through the AB-8 type macroporous adsorption resin, the amount of macroporous adsorption resin is 1.8kg, and the loading speed is 6 times column volume/hour. First elute with 6 column volumes of water. The water eluate was discarded. Then, the column was eluted with 5 column volumes of 95% ethanol, and the alcohol eluate was combined. The ethanol was recovered under reduced pressure at 70 Torr to a relative density of 1.25, dried under vacuum, and the dry paste was pulverized through an 80 mesh sieve.
  • Lactose was added to the obtained dry paste to prepare a capsule.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the precipitate was washed with water to a pH of 5-6, dried, and the granules were pulverized through an 80 mesh sieve to obtain a Coptidis extract.
  • the remaining 8 herbs were added with 10 times their weight and refluxed twice for 1 hour each time; the extract was concentrated under reduced pressure to a relative density of 1.03, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; The solution was filtered, and ethanol was recovered to a relative density of 1.35, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula 833g of Tianhua powder, 667g of Bupleurum, 500g of medlar, 167g of rhubarb, 333g of Pinellia, 500g of Radix Astragali, 333g of Rhizoma Coptidis, 500g of Radix Paeoniae, 833g of ebony and 500g of Hawthorn.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 10 herbs were extracted twice with 10 times the weight of water, and the extract was filtered for 1.5 hours each time.
  • the extract was concentrated under reduced pressure until the ratio of the original drug weight (kg) to the volume (L) of the concentrate was 1 : 1 , Add 95% ethanol to 70% alcohol content, filter, and concentrate to a thick paste under reduced pressure.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica sinensis, Radix Paeoniae Alba, Rhubarb, Astragalus, and Rhizoma Coptidis are extracted twice with 10 times their weight of 80% ethanol, 1.5 hours each time, and the extract is filtered and used;
  • the ratio of the original medicinal material weight (kg) to the volume (L) of the concentrate is 1: 1, adding 95% ethanol to 70% alcohol content, filtered, and set aside;
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the above 10 herbs were added to the water for 2 times, and 51.7 kg of water was added each time for 1 hour each time. Let the extract cool down, filter, and combine.
  • the AB-8 type macroporous adsorption resin has a macroporous adsorption resin dosage of 2.6 kg and a loading speed of 5 column volumes per hour. First elute with 5 column volumes of water. The water eluate was discarded. Then, the column was eluted with 3 column volumes of 90% ethanol, and the alcohol eluate was combined. The ethanol was recovered under reduced pressure at 70 ° C to a relative density of 1.30, and vacuum dried at 80 ° C. The dry paste is pulverized through an 80 mesh sieve.
  • a concentrated pellet was prepared by adding microcrystalline cellulose to the obtained dry paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 8 herbs were added with 10 times their weight of water for 2 times, one hour each time; the extract was concentrated under reduced pressure to a relative density of 1.05, let cool, add 95% ethanol, and make the alcohol content 70%; The solution was filtered, and the ethanol was recovered to a relative density of 1.30, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula 500g of trichosanthes, 750g of Bupleurum, 500g of medlar, 250g of rhubarb, 500g of Pinellia, 500g of Radix Astragali, 500g of Rhizoma Coptidis, 500g of Radix Paeoniae, 500g of Wumei, 500g of Hawthorn and 500g of Hawthorn.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 10 herbs were extracted twice with 10 times the weight of water, and the extract was filtered for 1.5 hours each time.
  • the extract was concentrated under reduced pressure until the ratio of the original drug weight (kg) to the volume (L) of the concentrate was 1 : 1, adding 95% ethanol to 70% alcohol content, filtered, concentrated under reduced pressure into a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica sinensis, Radix Paeoniae Alba, Rhubarb, Astragalus, and Rhizoma Coptidis are extracted twice with 10 times their weight of 80% ethanol, 1.5 hours each time, and the extract is filtered and used;
  • the extract is decompressed and concentrated.
  • the ratio of the original medicinal material weight (kg) to the volume (L) of the concentrate is 1:1, 95% ethanol is added to the alcohol content 70%, filtered, and used; The two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the above 10 herbs were added to the water for 2 times, and 50 kg of water was added each time for 1 hour. Let the extract cool down, filter, and combine. After the AB-8 type macroporous adsorption resin, the amount of the macroporous adsorption resin is 2.5 kg, and the loading speed is 4 times the column volume/hour. First elute with 5 column volumes of water. The water eluate was discarded. Then, the column was eluted with 4 column volumes of 92% ethanol, and the alcohol eluate was combined. The ethanol was recovered under reduced pressure at 75 ° C to a relative density of 1.25, vacuum dried at 85 ° C, and the dry paste was pulverized through an 80 mesh sieve.
  • a dextrin was added to the obtained dry paste to prepare a tablet.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 8 herbs were added with 10 times their weight and refluxed twice for 1 hour each time; the extract was concentrated under reduced pressure to a relative density of 1.05, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; The solution was filtered, and the ethanol was recovered to a relative density of 1.25, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula Trichosanthin 1200g, Bupleurum 800g, medlar 600g, Rhubarb 200g, Pinellia 400g, Radix Scutellariae 400g, Coptis 200g, Angelica 400g, Wumei 400g and Hawthorn 400g.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 10 herbs were extracted twice with 10 times the weight of water and refluxed for 1.5 hours each time.
  • the extract was filtered, and the extract was concentrated under reduced pressure until the ratio of the original drug weight (kg) to the volume (L) of the concentrate was 1 : 1, adding 90% ethanol to 68% alcohol content, filtered, concentrated under reduced pressure into a thick paste.
  • Example 30 Using the same formulation as in Example 29, the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica sinensis, Radix Paeoniae Alba, Rhubarb, Astragalus, and Rhizoma Coptidis are refluxed twice with 10 times the weight of 85% ethanol, 1.5 hours each time, the extract is filtered and used;
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method - the above 10 herbs were refluxed twice with water, and 50 kg of water was added each time for 1 hour. Let the extract cool down, filter, and combine. After the AB-8 type macroporous adsorption resin, the amount of the macroporous adsorption resin is 2.0 kg, and the loading speed is 6 times the column volume/hour. First elute with 4 column volumes of water. The water eluate was discarded. Then, the column was eluted with 3 column volumes of 92% ethanol, and the alcohol eluate was combined. The ethanol was recovered under reduced pressure at 65 ° C to a relative density of 1.30, vacuum dried at 75 ° C, and the dry paste was pulverized through an 80 mesh sieve.
  • a lactose is added to the obtained dry paste to prepare a capsule.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 8 herbs were added with 10 times their weight and refluxed twice for 1 hour each time; the extract was concentrated under reduced pressure to a relative density of 1.05, allowed to cool, and 95% ethanol was added to make the alcohol content 70%; The solution was filtered, and ethanol was recovered to a relative density of 1.35, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Drug formula Tianhua powder 1000g, Bupleurum 600g, tamping 600g, rhubarb 250g, Pinellia 300g, yellow ⁇ 500g, berberine 300g, white peony 500g, ebony 500g and hawthorn 300g.
  • the pharmaceutical composition of the present invention is prepared as follows:
  • the 10 herbs were extracted twice with 10 times the weight of water and refluxed for 1.5 hours each time.
  • the extract was filtered, and the extract was concentrated under reduced pressure until the ratio of the original drug weight (kg) to the volume (L) of the concentrate was 1 : 1 , Add 99% ethanol to 74% alcohol content, filter, and concentrate to a thick paste under reduced pressure.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • Bupleurum, Angelica, Rhizoma, Rhubarb, Astragalus, and Rhizoma Coptidis are extracted twice with 10 times their weight of 90% ethanol, 1.5 hours each time, the extract is filtered and used;
  • the extract is concentrated under reduced pressure.
  • the ratio of the original medicinal material weight (kg) to the volume (L) of the concentrate is 1: 1, 99% ethanol is added to the alcohol content 74%, filtered, spare
  • the two extracts were mixed and concentrated under reduced pressure to a thick paste.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the above 10 herbs were added to the water for 2 times, and each time 48.5 kg of water was added, one hour each time.
  • the extract is allowed to cool, filtered, and combined.
  • the amount of macroporous adsorption resin is 1.7kg, and the loading speed is 5 times column volume/hour.
  • the water eluate was discarded.
  • the alcohol eluate was eluted with 5 column volumes of 85% ethanol, and the ethanol was recovered under reduced pressure at 70 Torr to a relative density of 1.35, dried under vacuum at 90 Torr, and the dry paste was pulverized through an 80 mesh sieve.
  • a lactose is added to the obtained dry paste to prepare a capsule.
  • the pharmaceutical composition of the present invention was prepared by the following method:
  • the remaining 8 herbs were added with 10 times their weight of water for 2 times, one hour each time; the extract was concentrated under reduced pressure to a relative density of 1.05, let cool, add 95% ethanol, and make the alcohol content 70%; The solution was filtered, and the ethanol was recovered to a relative density of 1.30, dried, and the dry paste was pulverized through an 80 mesh sieve.
  • Streptozotocin American sigma company, batch number 024K1211;
  • Anhydrous citric acid (C 6 H 8 O r H 2 0): Tianjin Chemical Reagent No. 1 Plant, batch No. 011121;
  • Metformin 250mg/tablet, produced by Tianjin Pacific Pharmaceutical Co., Ltd., batch number 040121;
  • the different prescription group drugs of the test examples were the extract powders prepared in accordance with Example 3, Example 8 and Example 9, respectively, and were numbered TL-1, TL-2 and TL-3, respectively.
  • the experimental data were expressed as mean ⁇ standard deviation ( ⁇ ), and the significance of the difference between the two groups was t test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

一种治疗糖尿病的药物及其制备方法 技术领域
本发明涉及治疗糖尿病的药物组合物的制备方法, 以及由所述方法制备得到的药 物组合物。 背景技术
糖尿病是由体内糖、 蛋白质和脂肪代谢紊乱而造成的一种慢性进行性终身疾病, 其特征性表现为高血糖和糖尿。 这种病将导致心脏和肾脏并发症、 眼盲和截肢。 近年 来从临床上观察, 糖尿病的发病率正在呈逐年上升趋势。 目前, 全世界约有 1. 5亿糖 尿病患者, 我国目前糖尿病人数已超过 4000万。 在糖尿病病例中, 少数为胰岛素依赖 型糖尿病 (I型), 大多数为非胰岛素依赖型糖尿病 ( Π型)。大多数的糖尿病患者需要终身 服药。 目前糖尿病治疗仍以化学合成药物为主, 如磺胺类、 双胍类、 葡萄糖苷酶抑制剂、 格列奈类和胰岛素增敏剂等。 但这些药物长期服用副作用均比较大。 中医药在防治糖尿病方面有着悠久的历史, 经过几千年的实践, 积累了大量的宝 贵经验, 形成了独特的学术体系。 中医药典籍记载了很多具有降糖疗效的中药, 如泽 泻、 知母、 西洋参、 葛根、 地黄、 花粉等。 传统的中医治疗糖尿病是根据临床症状进 行三消论治。 但在糖耐量减低期及糖尿病发病的早期却没有很好的治疗办法。
糖尿病之位首责于肝胃,郁热内蕴是消渴病的病理基础, "木郁达之"、 "土郁夺之", 故当以疏导为主, SP"必伏其所主, 而先其所因"。 糖敏灵开郁清胃, 滋阴降火, 通腑 泻浊, 标本兼治, 郁热既清, 则气阴自复。 《证治准绳 ·消瘅》 云: "使道路散而不结, 津液生而不枯, 气血和而不涩, 则病自已矣。 ", 因此, 糖尿病的治疗以开郁清胃, 滋 阴降火, 通腑泻浊。 根据传统的中医药理论, 过食少动所引起的胃肠郁滞, 使中焦大气转运受阻, 大 气不转, 肝胆之疏泄亦郁闭, 郁而化热, 出现肝胆胃肠肺等三焦之热。 故以黄连, 大 黄为君, 黄连清胃热, 大黄清泻肠热, 此乃以苦治甜。 白芍、 黄芩、 柴胡为臣, 白芍 柔肝敛阴, 佐君以清三焦之热而不伤阴, 柴胡入少阳胆经和厥阴肝经, 清肝胆之热, 疏泄脾胃, 黄芩清肝肺之热。 枳实、 生山楂理气消食导滞, 合大黄以畅肠胃, 半夏合 黄连辛开苦降, 开畅中焦, 故为佐。 乌梅酸以敛阴生津, 此乃酸以制甜, 合天花粉以 救肺胃之阴, 故应称之谓使也。 本发明人以中医"郁热"学说为理论依据, 研究发现, 由天花粉、 柴胡、 枳实、 大 黄、 半夏、 黄芩、 黄连、 白芍、 乌梅等药材组成的组合物对糖尿病具有很好的治疗作 用。所述药物公开在本申请人早期的专利申请 200410020220.7之中, 但是, 该专利申请 中采用了传统的醇提方法, 用该方法得到的提取物损失了大量的水溶性有效成分; 不 仅收率低, 而且有效成分的含量很小, 所以给药剂量很大, 相应的副作用也会增加。 发明内容
本发明的目的在于提供了一种具有下述组成的, 用于治疗糖尿病的药物组合物, 该药物组合物是由本发明的下述的方法制成的, 从而解决了现有技术中存在的上述问 题。 本发明的又一目的是提供了本发明药物组合物的制备方法, 所述的药物组合物含 有如下重量份的生药材制备的提取物:天花粉 5-40份、柴胡 10-30份、枳实 3-15份、 大黄 1-6份、半夏 1-12份、黄芩 3-15份、黄连 1-12份、 白芍 3-15份和乌梅 5-20份, 并任选含有药学上可接受的辅料; 该组合物用下述方法之一制备:
方法一, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将所述药材加水回流提取, 提取液过滤、 减压浓缩;
(3) 在浓缩液中加入乙醇至含醇量为 65-75%, 过滤;
(4) 将滤液减压浓缩成浸膏;
(5 ) 任选的在上述浸膏中加入辅料制成药剂学上可接受的剂型; 方法二, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将所述药材加水回流提取, 将提取液放凉、 过滤、 合并得滤液;
(3 ) 将滤液过大孔吸附树脂, 用水洗脱, 弃去, 继续用一定浓度的乙醇洗 脱, 合并洗脱液, 减压回收乙醇得浸膏;
(4) 任选的在上述浸膏中加入辅料制成药剂学上可接受的剂型; 方法三, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将其中的药材柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用一定浓度的乙 醇回流提取, 将将提取液放凉、 过滤、 合并; (3 ) 在上一步骤所得到的药渣中加入其他药材, 加水回流提取, 提取液减 压浓缩, 浓缩液加入乙醇至含醇量为 65-75%, 过滤;
(4) 将 (2) 和 (3 ) 所得滤液合并, 浓缩成浸膏;
(5 ) 任选的在上述浸膏中加入辅料制成药剂学上可接受的剂型; 方法四, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将黄芩加水回流提取, 合并提取液, 调 pH值至 1.5-2.0; 保温, 静置, 滤过, 沉淀用水洗 pH值至 5-6, 干燥, 得黄芩提取物干粉;
(3 ) 将黄连加乙醇回流提取, 合并提取液, 滤过, 回收乙醇至无醇味, 调 pH值至 1-2; 冷藏过夜, 滤过, 沉淀用水洗 pH值至 5-6, 干燥, 得黄连提取物 干粉;
(4)将其他药材加水回流提取, 提取液合并, 浓缩, 放凉, 加入 95%乙醇, 使提取液的含醇量达到 70%; 静置, 滤过, 回收乙醇得浸膏; 干燥, 得提取物干 粉; 和
(5 ) 将上述三个步骤得到的提取物干粉混合均勾; 并任选的加入辅料制成 药剂学上可接受的剂型。 用本发明方法制备的药物组合物中, 各种生药材优选的重量比为: 天花粉 9份、 柴胡 12份、 枳实 9份、 大黄 3份、 半夏 6份、 黄芩 9份、 黄连 6份、 白芍 9份和乌 梅 9份。 进一步的, 在上述药物配方的基础上, 本发明的药物组合物在其配方中还可以加 入山楂, 这是因为山楂酸甘化阴, 既可以防辛散太过伤阴, 又可苦酸制甜。 配伍开郁 清热具有很好的疗效。 因此, 优选的技术方案是各种生药材的重量份数比为: 天花粉 5-40份、 柴胡 10-30份、 枳实 3-15份、 大黄 1-6份、 半夏 1-12份、 黄芩 3-15份、 黄 连 1-12份、 白芍 3-15份、 乌梅 5-20份和山楂 3-15份。 因此,更优选本发明药物组合物中各种生药材的重量份数比为:天花粉 10-30份、 柴胡 10-30份、 枳实 3-15份、 大黄 1-6份、 半夏 1-12份、 黄芩 3-15份、 黄连 1-12 份、 白芍 3-15份、 乌梅 5-20份和山楂 3-15份。 最优选的, 本发明药物组合物中各种生药材的重量份数比为: 天花粉 30 份、 柴 胡 12份、 枳实 9份、 大黄 3份、 半夏 6份、 黄芩 9份、 黄连 6份、 白芍 9份、 乌梅 15份和山楂 9份; 或者是天花粉 15份、 柴胡 12份、 枳实 9份、 大黄 3份、 半夏 6 份、 黄芩 9份、 黄连 6份、 白芍 9份、 乌梅 15份和山楂 9份。
具体的, 在本发明上述的方法一中, 优选采用下述操作条件:
1、 在步骤(2) 中, 优选回流提取两次, 每次用 10倍于所述药材重量的水, 每次 1.5小时。优选提取液浓缩至最初的药材重量(kg)和浓縮液的体积(L)之比为 1 : 1。
2、 在步骤(3 ) 中, 加入的乙醇浓度优选为 90-100%, 优选为 95%。 加入乙醇后, 所得到的浓缩液的含醇量优选为 70%。 由于采用了本发明上述水提醇沉的提取方法, 由该方法制备得到的中药组合物中 有效成分的含量明显提高, 杂质的含量明显减少, 从而可减少给药的剂量。
在本发明上述的方法二中, 优选釆用下述操作条件:
1、 在步骤 (2) 中, 优选加水回流提取两次, 每次用 10倍于所述药材重量的水, 每次提取 1小时。
2、在步骤(3 )中, 大孔树脂优选为 AB-8型。树脂和药材重量比优选为 1 : 1.5-1: 3, 进一步优选为 1 : 2。 提取液的上样速度优选为 4-6倍柱体积 /小时。 水洗量优选为 4-6倍柱体积。 用于洗脱的乙醇浓度优选为 80%-95%, 进一步优选为 90%。 乙醇用量 优选为 2-5倍柱体积。 减压回收乙醇的温度优选为 60-80°C, 减压回收乙醇得到浸膏, 浸膏的相对密度为 1.25-1.35, 优选为相对密度为 1.30。 本发明的上述制备方法釆用了水提工艺, 可以保证水溶性有效成分, 如柴胡皂苷、 黄连素 (盐酸小檗碱)、 黄芩苷、 大黄酚、 芍药苷、 辛弗林等得到最大程度的提取; 采 用大孔树脂吸附、 水洗去杂质、 乙醇水溶液洗脱有效成分的提取步骤, 在保留有效成 分的同时, 去除了其中大部分的杂质。 采用上述制备方法, 本发明的中药组合物中有效成分的含量明显提高, 杂质的含 量大大减少, 从而减少了给药的剂量, 同时也保证了产品批次之间的稳定性。 在本发明上述的方法三中, 优选采用下述操作条件:
1、在步骤(2 )中, 所用乙醇的浓度为 75-90%, 优选为 80%; 优选回流提取两次, 每次用 10倍于步骤 (2) 所述药材重量的乙醇, 每次提取 1.5小时。
2、 在步骤 (3 ) 中, 优选将上一步骤所得到的药渣中加入其他药材, 用水回流提 取两次, 每次水的用量为步骤 (3 ) 加入的其他药材与步骤 (2) 得到的药渣的重量之 和的 10倍, 每次提取 1.5小时。 优选把提取液浓縮至最初的药材重量 (kg) 和浓縮液 的体积 (L) 之比为 1 : 1。 所加入的乙醇浓度优选为 90-100%, 进一步优选为 95%, 使浓缩液的含醇量达到 65-75 % , 优选 70%。 在本发明的上述制备方法中, 柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连等生药材先 醇提, 残渣再与其他药材合并水提, 保证了这六味药材有效成分得到充分提取; 其他 药材仅用水提取其中的有效成分, 这是因为其中的有效成分都是水溶性。 釆用本发明 的上述方法使本发明的中药组合物中的有效成分含量明显提高, 杂质含量大大减少, 从而可减少给药的剂量。
在本发明上述的方法四中, 优选采用下述操作条件:
1、 步骤 (2) 中, 优选用水回流提取两次, 每次用 10倍于黄芩重量的水, 每次 1 小时。 保温温度优选为 75-85Ό , 进一步优选为 80°C。
2、 步骤(3 ) 中, 优选用乙醇回流提取两次, 每次用 10倍于黄连重量的乙醇, 每 次 2小时。 所用乙醇的浓度优选为 70-85%, 进一步优选为 75%。
步骤 (2) 和步骤 (3 ) 中, pH调节剂优选为浓盐酸。
3、 步骤 (4) 中, 优选用水回流提取其余药材 2次, 每次加 10倍于步骤 (4) 中 所述药材重量的水, 每次 1小时。 合并后的提取液浓缩至相对密度为 1.03-1.07, 优选 为相对密度为 1.05。 回收乙醇后, 将乙醇提取液浓縮至相对密度为 1.25-1.35的浸膏, 优选为相对密度为 1.30。 在本发明的上述方法中, 将黄芩、 黄连和其他药材分别单独提取, 并根据其自身 的性质分别在一定的 pH值条件下进行水提或醇提, 使本发明中药组合物中的有效成 分含量明显提高, 杂质含量大大减少, 从而减少了给药的剂量。 用本发明的上述方法可制备得到具有上述组成的、用于治疗糖尿病的药物组合物, 本发明的药物组合物可以采用中药制剂的常规方法, 使用本领域常规的辅料, 制备成 任何常规的制剂。 例如将上述原料药研成散剂冲服, 或将制成的浸膏干燥、 粉碎、 过 筛后, 研成散剂冲服, 或将其制成片剂或胶囊口服, 或者将其制成注射剂等。 但是这 些不能用于限制本发明的保护范围。 用本发明的方法制备得到的药物组合物具有降低血糖的作用, 对糖尿病有良好的 治疗效果。 本文中, 当用百分数描述乙醇浓度或含醇量 (即体系中含有乙醇的量) 时, 如果 没有特别说明, 是指体积百分比浓度或体积百分数。
具体实施方式
下面通过实施例和试验例进一步说明本发明的药物及其有益效果, 但不以任何方 式限制本发明的保护范围。 实施例 1
药物配方: 天花粉 750g、 柴胡 1500g、 枳实 450g、 大黄 150g、 半夏 150g、 黄 芩 450g、 黄连 150g、 白芍 450g和乌梅 750g。 按照下述方法制备本发明的药物组合物:
9味药材用 10倍于其重量的水回流提取 2次, 每次 1.5小时, 将提取液滤过, 将 提取液减压浓缩至最初的药材重量(kg)和浓缩液的体积(L)之比为 1 : 1, 加入 90% 乙醇至含醇量 65%, 过滤, 减压浓縮成稠膏。 实施例 2
采用实施例 1同样的配方, 用下述方法制备本发明的药物组合物:
将柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 75%乙醇回流提取 2 次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、乌梅和半夏, 用 10倍于所述药材和药渣重 量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓缩至最初的药材重量(kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 90%乙醇至含醇量 65%, 滤过, 备用;
将两提取液混合, 减压浓縮成稠膏。 实施例 3
采用实施例 1同样的配方, 用下述方法制备本发明的药物组合物:
以上 9味药材加水回流提取 2次, 每次加水 48.5kg, 每次 1小时。将提取液放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 3.2kg, 上样速度为 4倍 柱体积 /小时。 先用 4倍柱体积的水洗脱, 弃去水洗脱液, 然后用 2倍柱体积的 80%乙 醇洗脱, 将醇洗脱液合并, 80Ό下减压回收乙醇至相对密度为 1.25, 70°C真空干燥, 干膏粉碎过 80目筛。 过筛后的干粉中加入乳糖制成胶囊。 实施例 4 采用实施例 1同样的配方, 用下述方法制备本发明的药物组合物:
将黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 75 °C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
将黄连加 10倍其重量的 70%乙醇回流提取两次,每次 2小时;合并提取液,滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗 pH值 至 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
将其余 7味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.03 , 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.25 , 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均匀, 向其中加入乳糖制成胶囊。 实施例 5
药物配方: 天花粉 1200g、 柴胡 900g、 枳实 450g、 大黄 180g、 半夏 360g、 黄 芩 450g、 黄连 360g、 白芍 450g和乌梅 600g。 按照下述方法制备本发明的药物组合物:
9味药材用 10倍其重量的水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓縮至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入无水乙 醇至含醇量 75%, 滤过, 减压浓缩成稠膏。 实施例 6
采用实施例 5同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、黄连用 10倍其重量 90%乙醇回流提取 2次, 每 次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、乌梅和半夏, 用 10倍于所述药材和药渣重 量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓縮至最初的药材重量(kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入无水乙醇至含醇量 75%, 滤过, 备用;
将两提取液混合, 减压浓缩成稠膏。
实施例 7
采用实施例 5同样的配方, 用下述方法制备本发明的药物组合物:
以上 9味药材加水回流提取 2次, 每次加水 49.5kg, 每次 1小时。将提取液放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 1.7kg, 上样速度为 6倍 柱体积 /小时。 先用 6倍柱体积的水洗脱, 弃去水洗脱液。 然后用 5倍柱体积的 95%乙 醇洗脱, 将醇洗脱液合并, 70Ό下减压回收乙醇至相对密度为 1.35, 90Ό真空干燥, 千膏粉碎过 80目筛。
在所得到的干膏中加入淀粉压成片剂。
实施例 8
采用实施例 5同样的配方, 用下述方法制备本发明的药物组合物:
黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸调 pH值至 1.5-2.0, 85 °C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干 膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 85%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗 pH值 至 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
其余 7味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压浓 缩至相对密度为 1.07, 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收乙 醇至相对密度为 1.35, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均匀, 向其中加入淀粉压成片剂。 实施例 9
药物配方:天花粉 630g 、柴胡 840g、枳实 630g、大黄 210g、半夏 420g、黄芩 630g、 黄连 420g、 白芍 630g和乌梅 630g。 按照下述方法制备本发明的药物组合物:
9味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取液 减压浓缩至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 95%乙醇 至含醇量 70%, 滤过, 减压浓缩成稠膏。
实施例 10
采用实施例 9同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 80%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅和半夏, 用 10 倍于所述药材和药渣 重量之和的水回流提取 2次,每次 1.5小时,将提取液减压浓缩至最初的药材重量(kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 95%乙醇至含醇量 70%, 滤过, 备用;
将两提取液混合, 减压浓缩成稠膏。
实施例 11
釆用实施例 9同样的配方, 用下述方法制备本发明的药物组合物:
以上 9味药材加水回流提取 2次, 每次加水 50.4kg, 每次 1小时。将提取液放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 2.52kg, 上样速度为 5 倍柱体积 /小时。 先用 5倍柱体积的水洗脱。 水洗脱液弃去。 然后用 3倍柱体积的 90% 乙醇洗脱, 将醇洗脱液合并, 70°C下减压回收乙醇至相对密度为 1.30, 80Ό真空干燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入微晶纤维素制成浓缩丸。
实施例 12
采用实施例 9同样的配方, 用下述方法制备本发明的药物组合物:
黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 80Ό保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 75%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
其余 7味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.05, 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.30, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均匀, 加入微晶纤维素制成浓缩丸。
实施例 13
药物配方: 天花粉 750g、 柴胡 1500g、 枳实 450g、 大黄 150g、 半夏 150g、 黄 芩 450g、 黄连 150g、 白芍 450g、 乌梅 750g和山楂 450g。 按照下述方法制备本发明的药物组合物:
10味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓缩至最初的药材重量 (kg) 和浓縮液的体积 (L) 之比为 1 : 1, 加入 90%乙 醇至含醇量 65%, 滤过, 减压浓缩成稠膏。
实施例 14
采用实施例 13同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 75%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅、 半夏和山楂, 用 10倍于所述药材 和药渣重量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓缩至最初的药材 重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1 , 加入 90%乙醇至含醇量 65%, 滤过, 备用;
将两提取液混合, 减压浓缩成稠膏。
实施例 15
采用实施例 13同样的配方, 用下述方法制备本发明的药物组合物- 以上 10味药材加水回流提取 2次, 每次加水 52.5kg, 每次 1小时。 将将提取液 放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 3.5kg, 上样速度 为 4倍柱体积 /小时。 先用 4倍柱体积的水洗脱。 水洗脱液弃去。 然后用 2倍柱体积的 80%乙醇洗脱, 将醇洗脱液合并, 80Ό下减压回收乙醇至相对密度为 1.35, 70Ό真空 干燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入乳糖制成胶囊。
实施例 16
采用实施例 13同样的配方, 用下述方法制备本发明的药物组合物:
黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 75°C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 70%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
其余 8味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.07, 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.25, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均匀, 加入乳糖制成胶囊。 实施例 17
药物配方: 天花粉 1200g、 柴胡 900g、 枳实 450g、 大黄 180g、 半夏 360g、 黄 芩 450g、 黄连 360g、 白芍 450g、 乌梅 600g和山楂 450g。 按照下述方法制备本发明的药物组合物:
10味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓縮至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入无水乙 醇至含醇量 75%, 滤过, 减压浓缩成稠膏。
实施例 18
采用实施例 17同样的配方, 用下述方法制备本发明的药物组合物- 柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 90%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅、 半夏和山楂, 用 10倍于所述药材 和药渣重量之和的水回流提取 2次每次 1.5小时, 将提取液减压浓缩至最初的药材重 量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入无水乙醇至含醇量 75%, 滤过, 备 用;
将两提取液混合, 减压浓縮成稠膏。
实施例 19
采用实施例 17同样的配方, 用下述方法制备本发明的药物组合物:
以上 10味药材加水回流提取 2次, 每次加水 54kg, 每次 1小时。 将提取液放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 1.8kg, 上样速度为 6倍 柱体积 /小时。 先用 6倍柱体积的水洗脱。 水洗脱液弃去。 然后用 5倍柱体积的 95%乙 醇洗脱, 将醇洗脱液合并, 70Ό下减压回收乙醇至相对密度为 1.25, 90Ό真空干燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入乳糖制成胶囊。
实施例 20
采用实施例 17同样的配方, 用下述方法制备本发明的药物组合物:
黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 80°C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 千燥, 干膏粉碎过 80目筛, 得黄芩提取物。 黄连加 10倍其重量的 70%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 千膏粉碎过 80目筛, 得黄连提取物。
其余 8味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.03 , 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.35, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均勾, 加入乳糖制成胶囊。 实施例 21
药物配方:天花粉 833g、柴胡 667g、枳实 500g、大黄 167g、半夏 333g、黄芩 500g 、 黄连 333g、 白芍 500g、 乌梅 833g和山楂 500g。 按照下述方法制备本发明的药物组合物:
10味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓缩至最初的药材重量 (kg) 和浓缩液的体积 (L ) 之比为 1 : 1 , 加入 95%乙 醇至含醇量 70%, 滤过, 减压浓缩成稠膏。
实施例 22
釆用实施例 21同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 80%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅、 半夏和山楂, 用 10倍于所述药材 和药渣重量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓缩至最初的药材 重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 95%乙醇至含醇量 70%, 滤过, 备用;
将两提取液混合, 减压浓缩成稠膏。
实施例 23
釆用实施例 21同样的配方, 用下述方法制备本发明的药物组合物:
以上 10味药材加水回流提取 2次, 每次加水 51.7kg, 每次 1小时。 将提取液放 凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 2.6kg, 上样速度为 5倍柱体积 /小时。先用 5倍柱体积的水洗脱。水洗脱液弃去。然后用 3倍柱体积的 90% 乙醇洗脱, 将醇洗脱液合并, 70°C下减压回收乙醇至相对密度为 1.30, 80°C真空干燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入微晶纤维素制成浓缩丸。
实施例 24
釆用实施例 21同样的配方, 用下述方法制备本发明的药物组合物:
黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 80°C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 75%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
其余 8味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.05 , 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.30, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均勾, 加入微晶纤维素制成浓缩丸。
实施例 25
药物配方: 天花粉 500g、 柴胡 750g、 枳实 500g、 大黄 250g、 半夏 500g份、 黄芩 500g、 黄连 500g、 白芍 500g、 乌梅 500g和山楂 500g。 按照下述方法制备本发明的药物组合物:
10味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓縮至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 95%乙 醇至含醇量 70%, 滤过, 减压浓缩成稠膏。
实施例 26
采用实施例 25同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 80%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅、 半夏和山楂, 用 10倍于所述药材 和药渣重量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓縮至最初的药材 重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 95%乙醇至含醇量 70%, 滤过, 备用; 将两提取液混合, 减压浓缩成稠膏。
实施例 27
采用实施例 25同样的配方, 用下述方法制备本发明的药物组合物:
以上 10味药材加水回流提取 2次, 每次加水 50kg, 每次 1小时。 将提取液放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 2.5kg, 上样速度为 4倍 柱体积 /小时。 先用 5倍柱体积的水洗脱。 水洗脱液弃去。 然后用 4倍柱体积的 92%乙 醇洗脱, 将醇洗脱液合并, 75°C下减压回收乙醇至相对密度为 1.25, 85°C真空干燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入糊精制成片剂。
实施例 28
釆用实施例 25同样的配方, 用下述方法制备本发明的药物组合物:
黄苓加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 85 °C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 85%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 千膏粉碎过 80目筛, 得黄连提取物。
其余 8味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.05, 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.25, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均匀, 加入糊精制成片剂。 实施例 29
药物配方: 天花粉 1200g、 柴胡 800g、 枳实 600g、 大黄 200g、 半夏 400g、 黄 芩 400g、 黄连 200g、 白芍 400g、 乌梅 400g和山楂 400g。 按照下述方法制备本发明的药物组合物:
10味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓缩至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 90%乙 醇至含醇量 68%, 滤过, 减压浓缩成稠膏。
实施例 30 采用实施例 29同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 85%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅、 半夏和山植, 用 10倍于所述药材 和药渣重量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓缩至最初的药材 重量 (kg) 和浓縮液的体积 (L) 之比为 1 : 1 , 加入 90%乙醇至含醇量 68%, 滤过, 备用;
将两提取液混合, 减压浓缩成稠膏。
实施例 31
采用实施例 29同样的配方, 用下述方法制备本发明的药物组合物- 以上 10味药材加水回流提取 2次, 每次加水 50kg, 每次 1小时。 将提取液放凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 2.0kg, 上样速度为 6倍 柱体积 /小时。 先用 4倍柱体积的水洗脱。 水洗脱液弃去。 然后用 3倍柱体积的 92%乙 醇洗脱, 将醇洗脱液合并, 65 °C下减压回收乙醇至相对密度为 1.30, 75 °C真空千燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入乳糖制成胶囊剂。
实施例 32
采用实施例 29同样的配方, 用下述方法制备本发明的药物组合物:
黄芩加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 75°C保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 75%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
其余 8味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.05, 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.35, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均匀, 加入乳糖制成胶囊剂。 实施例 33
药物配方: 天花粉 1000g、 柴胡 600g、 枳实 600g、 大黄 250g、 半夏 300g、 黄 芩 500g、 黄连 300g、 白芍 500g、 乌梅 500g和山楂 300g。 按照下述方法制备本发明的药物组合物:
10味药材用 10倍其重量水回流提取 2次, 每次 1.5小时, 提取液滤过, 将提取 液减压浓缩至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1 , 加入 99%乙 醇至含醇量 74%, 滤过, 减压浓缩成稠膏。
实施例 34
釆用实施例 33同样的配方, 用下述方法制备本发明的药物组合物:
柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用 10倍其重量的 90%乙醇回流提取 2次, 每次 1.5小时, 提取液滤过, 备用;
在上一步骤得到的药渣中加入天花粉、 乌梅、 半夏和山楂, 用 10倍于所述药材 和药渣重量之和的水回流提取 2次, 每次 1.5小时, 将提取液减压浓缩至最初的药材 重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1, 加入 99%乙醇至含醇量 74%, 滤过, 备用
将两提取液混合, 减压浓缩成稠膏。
实施例 35
釆用实施例 33同样的配方, 用下述方法制备本发明的药物组合物:
以上 10味药材加水回流提取 2次, 每次加水 48.5kg, 每次 1小时。 将提取液放 凉, 过滤, 合并。 过 AB-8型大孔吸附树脂, 大孔吸附树脂用量为 1.7kg, 上样速度为 5倍柱体积 /小时。先用 4倍柱体积的水洗脱。水洗脱液弃去。然后用 5倍柱体积的 85% 乙醇洗脱, 将醇洗脱液合并, 70Ό下减压回收乙醇至相对密度为 1.35, 90Ό真空干燥, 干膏粉碎过 80目筛。
在所得到的干膏中加入乳糖制成胶囊剂。
实施例 36
采用实施例 33同样的配方, 用下述方法制备本发明的药物组合物:
黄苓加 10倍其重量的水, 回流提取两次, 每次 1小时; 合并提取液, 加浓盐酸 调 pH值至 1.5-2.0, 80Ό保温 1小时, 静置, 滤过; 沉淀用水洗至 pH值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄芩提取物。
黄连加 10倍其重量的 80%乙醇回流提取两次, 每次 2小时; 合并提取液, 滤过, 回收乙醇至无醇味, 加入浓盐酸调 pH值至 1-2, 冷藏过夜, 滤过; 沉淀用水洗至 pH 值 5-6, 干燥, 干膏粉碎过 80目筛, 得黄连提取物。
其余 8味药材加 10倍其重量的水回流提取 2次, 每次 1小时; 提取液合并减压 浓缩至相对密度为 1.05 , 放凉, 加入 95%乙醇, 使含醇量为 70%; 静置, 滤过, 回收 乙醇至相对密度为 1.30, 干燥, 干膏粉碎过 80目筛。
取三种提取物干粉, 混合均勾, 加入乳糖制成胶囊剂。 试验例 1 药效试验
1 ) 实验动物:
SPF级雄性 SD大鼠, 60只, 体重 200-220g。
2) 主要试剂、 药品和仪器:
链脲佐菌素 (Streptozotocin、 STZ): 美国 sigma公司, 批号 024K1211 ;
无水柠檬酸 (C6H8OrH20): 天津化学试剂一厂, 批号 011121 ;
柠檬酸钠 (Na3C6H50 2H2O): 天津化学试剂一厂, 批号 011219;
二甲双胍: 250mg/片, 天津太平洋制药有限公司生产, 批号 040121 ;
试验例的不同处方组药物分别为按照实施例 3、 实施例 8和实施例 9制备的浸膏 粉, 编号分别为 TL-1, TL-2和 TL-3。
稳毫型血糖仪 (One-Touch Ultra): 美国 Lifescan公司, 注册号 20032400735。
3 ) 模型制备:
SD大鼠适应 1周后隔夜禁食, 经腹腔注射 STZ 65mg/kg (0.1mmol/l pH4.4柠檬 酸缓冲液制成 2% (W/V)的溶液), 3天后尾静脉取血测血 ¾≥16.7mmol/L为造模成功。 4) 给药方法及观察指标- 成模的糖尿病大鼠随机分成模型组、 二甲双胍 125mg/kg组和不同处方组 (用药 量相当于生药 15.5g/kg)。 适应一周, 检测血糖后灌胃给药, 每日一次, 药物皆用生理 盐水配制成混悬液给药, 实验期间皆自由摄食饮水, 实验周期 15天。 在给药第 7、 14 天, 给药后禁食 2小时, 尾静脉取血 one-touch ultra血糖仪测定血糖, 同时检测大鼠的 体重。
5 ) 统计学处理:
实验数据用均数±标准差 (^±^ ) 表示, 两组间差异显著性采用 t检验。
6) 结果 由表 1可见,不同处方组在用药量相当于生药 15.5g /kg剂量时,给药 7、 14天后, 均使 STZ高血糖大鼠的血糖明显下降 (P<0.01 )。
表 1. 各组血糖的变化及比较 ( ± 5Ώ η= 10) 剂 fi 给药前血糖 给药后 7天 给药后 14天
(mmol/1) (mmol/1) (mmol/1) 对照组 一 5.99±0.202 6.06±0.165 6.01±0.223 模型组 一 21.47±2.351* 22.35土 1.707' 22.33±1.614* 二甲双胍组 125mg/kg 21.61±2.066* 18.64±0.783*A 17.54±1.222*A
TL-1 生药 15.5 g /kg 21.48±1.686* 18.13±1.103*A 17.21±1.214*A
TL-2 生药 15.5 g /kg 21.62±1.734* 17.97±0.687*A 17.04±1.431*A
TL-3 生药 15.5 g /kg 21.53±1.752* 17.32±0.625*A 17.02士 1.256* A 注: *与对照组比较 p<0.01 ; A与模型组比较 p<0.01。

Claims

权利要求
1、一种治疗糖尿病的药物组合物的制备方法,其特征在于所述药物组合物含有如 下重量份的生药材制备的提取物: 天花粉 5-40份、 柴胡 10-30份、 枳实 3-15份、 大 黄 1-6份、 半夏 1-12份、 黄芩 3-15份、 黄连 1-12份、 白芍 3-15份和乌梅 5-20份, 并任选含有药学上可接受的辅料; 该组合物用下述方法之一制备:
方法一, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将所述药材加水回流提取, 提取液过滤、 减压浓缩;
(3 ) 在浓缩液中加入乙醇至含醇量为 65-75%, 过滤;
(4) 将滤液减压浓縮成浸膏;
(5 ) 任选的, 在浸膏中加入辅料制成药剂学上可接受的剂型; 方法二, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将所述药材加水回流提取, 将提取液放凉、 过滤、 合并得滤液;
(3 ) 将滤液过大孔吸附树脂, 用水洗脱, 弃去洗脱液, 继续用一定浓度的 乙醇洗脱, 合并乙醇洗脱液, 减压回收乙醇得浸膏;
(4) 任选的, 在浸膏中加入辅料制成药剂学上可接受的剂型; 方法三, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将其中的药材柴胡、 白芍、 枳实、 大黄、 黄芩、 黄连用一定浓度的乙 醇回流提取, 将提取液放凉、 过滤、 合并;
(3 ) 在上一步骤所得到的药渣中加入其他药材, 加水回流提取, 提取液减 压浓缩, 浓缩液加入乙醇至含醇量为 65-75%, 过滤;
(4) 将 (2) 和 (3 ) 所得滤液合并, 浓縮成浸膏;
(5 ) 任选的, 在浸膏中加入辅料制成药剂学上可接受的剂型; 方法四, 包括以下步骤:
( 1 ) 按照所述重量份数比取所需的药材;
(2) 将黄芩加水回流提取, 合并提取液, 调 pH值至 1.5-2.0; 保温, 静置, 滤过, 沉淀用水洗至 pH值 5-6, 干燥, 得黄芩提取物干粉;
(3 ) 将黄连加乙醇回流提取, 合并提取液, 滤过, 回收乙醇至无醇味, 调 pH值至 1-2; 冷藏过夜, 滤过, 沉淀用水洗至 pH值 5-6, 干燥, 得黄连提取物 干粉;
(4)将其他药材加水回流提取, 提取液合并, 浓縮, 放凉, 加入 95%乙醇, 使提取液的含醇量为 70%; 静置, 滤过, 回收乙醇得浸膏; 干燥, 得提取物干粉; 禾口
( 5 ) 将上述三个步骤得到的提取物干粉混合均匀; 并任选的加入辅料制成 药剂学上可接受的剂型。
2、 权利要求 1所述的药物组合物的制备方法, 其特征在于各药材的重量份为: 天 花粉 9份、 柴胡 12份、 枳实 9份、 大黄 3份、 半夏 6份、 黄芩 9份、 黄连 6份、 白 芍 9份和乌梅 9份。
3、 权利要求 1或 2所述药物组合物的制备方法, 其特征在于用于制备所述药物组 合物的药材还包括山楂, 所述各药材的重量份为: 天花粉 5-40份、 柴胡 10-30份、 枳 实 3-15份、 大黄 1-6份、 半夏 1-12份、 黄芩 3-15份、 黄连 1-12份、 白芍 3-15份、 乌梅 5-20份和山楂 3-15份。
4、 权利要求 3所述药物组合物的制备方法, 其特征在于各药材的重量份为: 天花 粉 10-30份、柴胡 10-30份、枳实 3-15份、大黄 1-6份、半夏 1-12份、黄芩 3-15份、 黄连 1-12份、 白芍 3-15份、 乌梅 5-20份和山楂 3-15份。
5、 权利要求 4所述药物组合物的制备方法, 其特征在于各药材的重量份为: 天花 粉 30份、 柴胡 12份、 枳实 9份、 大黄 3份、 半夏 6份、 黄芩 9份、 黄连 6份、 白芍 9份、 乌梅 15份和山楂 9份, 或各药材的重量份为: 天花粉 15份、 柴胡 12份、 枳 实 9份、大黄 3份、半夏 6份、黄芩 9份、黄连 6份、 白芍 9份、乌梅 15份和山楂 9 份。
6、 权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法一, 步骤 (2)中, 回流提取两次, 每次用 10倍于所述药材重量的水, 每次 1.5小时, 将提取液 浓缩至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1; 以及步骤 (3 ) 中, 加入的乙醇浓度为 90-100%。
7、 权利要求 6所述药物组合物的制备方法, 其特征在于方法一, 步骤(3 ) 中, 加 入的乙醇浓度为 95%; 加入乙醇后, 浓缩液的含醇量为 70%。
8、 权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法二, 步骤
(2) 中, 加水回流提取两次, 每次用 10倍于所述药材重量的水, 每次 1小时。
9、 权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法二, 步骤
(3 ) 中, 所述的大孔树脂为 AB- 8型; 树脂和药材的重量比为 1 : 1.5-1: 3。
10、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法二, 步骤 (3 ) 中, 提取液的上样速度为 4-6倍柱体积 /小时; 水洗量为 4-6倍柱体积; 用于洗脱 的乙醇浓度为 80%-95%; 优选的乙醇浓度为 90%; 洗脱用乙醇量为 2-5倍柱体积。
11、 权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法二, 步骤 (3 )中,减压回收乙醇的温度为 60-80Ό,减压回收乙醇至浸膏的相对密度为 1.25-1.35。
12、 权利要求 11所述药物组合物的制备方法, 其中所得浸膏的相对密度为 1.30。
13、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法三, 步骤
(2) 中, 用乙醇回流提取两次, 每次用 10倍于步骤 (2 )所述药材重量的乙醇, 每次 提取 1.5小时; 所用乙醇浓度为 75-90%, 优选 80%。
14、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法三, 步骤
(3 ) 中, 将上一步骤所得到的药渣中加入其他药材, 用水回流提取两次, 每次水的用 量为步骤(3)加入的其他药材与步骤 (2)得到的药渣的重量之和的 10倍, 每次提取 1.5小时; 提取液浓缩至最初的药材重量 (kg) 和浓缩液的体积 (L) 之比为 1 : 1。
15、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法三, 步骤 (3 )中,加入的乙醇浓度为 90-100%,优选 95%; 加入乙醇后浓缩液的含醇量为 70%。
16、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法四, 步骤
(2) 中, 用水回流提取两次, 每次加 10倍于黄芩重量的水, 每次 1小时; 提取液保 温温度为 75-85 °C, 优选保温温度为 80°C。
17、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法四, 步骤
(3 ) 中, 用乙醇回流提取两次, 每次加 10倍于黄连重量的乙醇, 每次 2小时; 乙醇 的浓度为 70-85%, 优选的乙醇浓度为 75%。
18、权利要求 1-5任意一项所述药物组合物的制备方法, 其特征在于方法四, 步骤 (2) 和 (3 ) 中, pH调节剂为浓盐酸。
19、权利要求 1-5任意一项所述的药物组合物的制备方法, 其特征在于方法四, 步 骤 (4) 中, 用水回流提取其余药材 2次, 每次加 10倍于步骤 (4) 中所述药材重量的 水,每次 1小时;合并后的提取液浓缩至相对密度为 1.03- 1.07;优选的相对密度为 1.05; 加入乙醇后, 回收乙醇得到浸膏, 其相对密度为 1.25-1.35, 优选的相对密度为 1.30。
20、 用权利要求 1-19任意一项所述的制备方法制备得到的药物组合物。
21、 权利要求 20所述的药物组合物, 其中所述组合物被制成任何药剂学上可接受 的剂型。
PCT/CN2008/001383 2007-08-02 2008-07-28 Composition pharmaceutique destinée au traitement du diabète et son procédé de préparation WO2009015557A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
RU2009144878/15A RU2485968C2 (ru) 2007-08-02 2008-07-28 Лекарственный препарат для лечения диабета и способ его изготовления
US12/601,236 US8637092B2 (en) 2007-08-02 2008-07-28 Pharmaceutical composition for treating diabetes and its process for preparation
DK08783574.0T DK2172207T3 (da) 2007-08-02 2008-07-28 Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf
JP2010518477A JP5508264B2 (ja) 2007-08-02 2008-07-28 糖尿病治療のための医薬組成物およびその製造方法
EP08783574A EP2172207B1 (en) 2007-08-02 2008-07-28 A pharmaceutical composition for treating diabetes and its process for preparation
AU2008281227A AU2008281227B2 (en) 2007-08-02 2008-07-28 A pharmaceutical composition for treating diabetes and its process for preparation
NZ581525A NZ581525A (en) 2007-08-02 2008-07-28 A pharmaceutical composition for treating diabetes and its process for preparation
BRPI0812792A BRPI0812792B8 (pt) 2007-08-02 2008-07-28 método para preparar uma composição farmacêutica para o tratamento de diabetes mellitus e dita composição farmacêutica
CA2687492A CA2687492C (en) 2007-08-02 2008-07-28 A herbal composition, method for preparing the same and use thereof for treating diabetes mellitus
KR1020107003490A KR101462984B1 (ko) 2007-08-02 2008-07-28 당뇨병 치료용 약학적 조성물 및 이의 제조 방법
HK10104520.9A HK1138206A1 (en) 2007-08-02 2010-05-10 A pharmaceutical composition for treating diabetes and its process for preparation

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2007100585744A CN101357183B (zh) 2007-08-02 2007-08-02 一种含有枳实的治疗糖尿病的药物及其制备方法
CN200710058571.0 2007-08-02
CN200710058572.5 2007-08-02
CN200710058573XA CN101357182B (zh) 2007-08-02 2007-08-02 一种含有乌梅的治疗糖尿病的药物及其制备方法
CN200710058573.X 2007-08-02
CNA2007100585710A CN101357180A (zh) 2007-08-02 2007-08-02 一种含有天花粉的治疗糖尿病的药物及其制备方法
CN2007100585725A CN101357181B (zh) 2007-08-02 2007-08-02 一种含有柴胡的治疗糖尿病的药物及其制备方法
CN200710058574.4 2007-08-02

Publications (1)

Publication Number Publication Date
WO2009015557A1 true WO2009015557A1 (fr) 2009-02-05

Family

ID=40303880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/001383 WO2009015557A1 (fr) 2007-08-02 2008-07-28 Composition pharmaceutique destinée au traitement du diabète et son procédé de préparation

Country Status (14)

Country Link
US (1) US8637092B2 (zh)
EP (1) EP2172207B1 (zh)
JP (1) JP5508264B2 (zh)
KR (1) KR101462984B1 (zh)
AR (1) AR070306A1 (zh)
AU (1) AU2008281227B2 (zh)
BR (1) BRPI0812792B8 (zh)
CA (1) CA2687492C (zh)
DK (1) DK2172207T3 (zh)
HK (1) HK1138206A1 (zh)
MY (1) MY154567A (zh)
NZ (1) NZ581525A (zh)
RU (1) RU2485968C2 (zh)
WO (1) WO2009015557A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103156938B (zh) * 2013-04-07 2014-08-13 贵州鸿德中药开发有限公司 一种治疗糖尿病的苗药
CN103610801B (zh) * 2013-11-19 2015-08-19 安徽宝芝堂药业有限公司 一种用于治疗伤寒热厥症的中药组合物
CN103599215A (zh) * 2013-11-28 2014-02-26 成都中医药大学附属医院 一种降糖药物
CN103784521B (zh) * 2014-01-21 2015-12-09 李桂霞 一种配合手术治疗腹腔脓肿的中药组合物及其制备方法
CN103784515B (zh) * 2014-02-11 2016-02-10 王思成 一种治疗口腔带状疱疹含漱液
CN107648424A (zh) * 2017-11-07 2018-02-02 贵州拜特制药有限公司 一种杞菊地黄制剂的制作方法
CN107875208A (zh) * 2017-11-29 2018-04-06 安徽海神寿春药业有限公司 一种黄连、大黄、黄芩复配的一清浸膏粉的生产方法
CN110898170B (zh) * 2018-09-17 2022-04-05 江苏九旭药业有限公司 一种治疗代谢综合征的中药组合物及其制剂
CN110237187A (zh) * 2019-06-03 2019-09-17 文山学院 一种黄精铁皮石斛口服液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726929A (zh) * 2004-07-30 2006-02-01 天津天士力制药股份有限公司 一种治疗糖尿病的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158600C1 (ru) * 1999-09-13 2000-11-10 Куркин Владимир Александрович Способ получения противодиабетического средства
JP5121038B2 (ja) 2000-12-22 2013-01-16 天士力製薬集団股分有限公司 狭心症のための薬草調合物、該薬草調合物を調合する方法、及びその使用法
US8486464B2 (en) 2000-12-22 2013-07-16 Tasly Pharmaceutical Group Co. Ltd. Herbal composition for angina pectoris, method to prepare same and uses thereof
JP5093965B2 (ja) * 2000-12-29 2012-12-12 キフアン ヤオヨケジ トウジ ヨウザイアン ゼレン ゴングシ 骨粗鬆症治療用Rhizoma Drynariaeエキス及びその抽出法
KR100402421B1 (ko) * 2001-07-30 2003-10-17 화천군 산사음료의 제조방법
RU2234224C2 (ru) * 2002-07-16 2004-08-20 Шиголаков Петр Васильевич Сухая питательная смесь "талган"
CN1725929B (zh) * 2004-07-21 2012-01-25 鸿富锦精密工业(深圳)有限公司 多灯管驱动系统

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1726929A (zh) * 2004-07-30 2006-02-01 天津天士力制药股份有限公司 一种治疗糖尿病的药物组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Clinical Practice from Shi Jinmo", CAPITCAL MEDICINE, vol. 24, no. 7, July 2003 (2003-07-01), pages 17 - 26, XP008137874 *
GONG XIANGJUN: "Therapeutical Development in Diabetes by TCM", CHINA'S NATUROPATHY, no. 1, January 1998 (1998-01-01), pages 63 - 65, XP008132026 *

Also Published As

Publication number Publication date
AU2008281227A1 (en) 2009-02-05
EP2172207A1 (en) 2010-04-07
KR101462984B1 (ko) 2014-11-18
RU2485968C2 (ru) 2013-06-27
HK1138206A1 (en) 2010-08-20
JP5508264B2 (ja) 2014-05-28
MY154567A (en) 2015-06-30
BRPI0812792A2 (pt) 2014-12-02
EP2172207A4 (en) 2010-07-28
CA2687492A1 (en) 2009-02-05
BRPI0812792B1 (pt) 2019-03-26
KR20100045478A (ko) 2010-05-03
AU2008281227B2 (en) 2013-03-28
JP2010535157A (ja) 2010-11-18
RU2009144878A (ru) 2011-09-10
AR070306A1 (es) 2010-03-31
CA2687492C (en) 2013-08-20
EP2172207B1 (en) 2013-01-02
NZ581525A (en) 2011-01-28
US20100136150A1 (en) 2010-06-03
US8637092B2 (en) 2014-01-28
BRPI0812792B8 (pt) 2021-05-25
DK2172207T3 (da) 2013-04-08

Similar Documents

Publication Publication Date Title
WO2009015557A1 (fr) Composition pharmaceutique destinée au traitement du diabète et son procédé de préparation
CN103705596A (zh) 一种降压中药及其制备方法
CN111388587A (zh) 一种用于制备治疗功能性消化不良药物的中药组合物
CN102526230B (zh) 一种治疗肝病的中药组合物、其制备方法和检测方法及应用
CN101357183B (zh) 一种含有枳实的治疗糖尿病的药物及其制备方法
CN1157200C (zh) 咽喉炎糖浆和颗粒剂及其制备方法
US10857186B2 (en) Traditional Chinese medicine composition for treating acute stage of cerebral infarction
TWI419698B (zh) Pharmaceutical composition for treating diabetes and its preparation method
CN103432386B (zh) 一种治疗咳嗽的中药制剂及其制备方法
CN108514627B (zh) 一种治疗慢性荨麻疹的中药组合物
CN105288128A (zh) 一种治疗糖尿病肾病的中药组合物及其制备方法
CN109078115A (zh) 一种用于消化道出血的中药制剂及其制备方法
CN1947752B (zh) 枳术宽中浓缩丸及其制备方法
CN114796417B (zh) 一种降血糖中药组方及其制备方法
CN104147229B (zh) 一种治疗女性更年期综合征肾阴阳两虚型的中药复方制剂
CN114588228B (zh) 一种治疗2型糖尿病的组合物
CN114259540B (zh) 一种治疗气阴两虚证糖尿病的中药组合物及其制备方法和用途
CN113521232B (zh) 一种含有白术的中药组合物
CN113018351B (zh) 一种药物组合物、药物制剂及其制备方法与应用
CN102485264A (zh) 一种治疗小儿久咳的药物组合物及其制备方法
CN102327526A (zh) 一种降血糖的中药组合物
CN101357182B (zh) 一种含有乌梅的治疗糖尿病的药物及其制备方法
CN106620440B (zh) 咳嗽处方
CN104547366A (zh) 一种治疗糖尿病的中药组合物
CN111035710A (zh) 一种治疗糖尿病的中药

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08783574

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2687492

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 6800/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008783574

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 581525

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008281227

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12601236

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010518477

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2008281227

Country of ref document: AU

Date of ref document: 20080728

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 20094878

Country of ref document: MY

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107003490

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009144878

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0812792

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091204